F. Hoffmann-La Roche AG


Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide. In 2016, Roche invested CHF 9.9 billion in R&D and posted sales of CHF 50.6 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

Roche retains sole responsibility for content © 2017 F. Hoffmann-La Roche Ltd. All trademarks used or mentioned in this release are protected by law.

1 March 2016 - 28 February 2017

Region: Global
Subject/journal group: All

The table to the right includes counts of all research outputs for F. Hoffmann-La Roche AG published between 1 March 2016 - 28 February 2017 which are tracked by the Nature Index.

Hover over the donut graph to view the WFC output for each subject. Below, the same research outputs are grouped by subject. Click on the subject to drill-down into a list of articles organized by journal, and then by title.

Note: Articles may be assigned to more than one subject area.

80 34.16 34.16

Outputs by subject (WFC)

Subject AC FC WFC
Life Sciences 55 22.53 22.53
Chemistry 28 12.76 12.76
Physical Sciences 1 0.65 0.65

Highlight of the month: F. Hoffmann-La Roche AG

Mutations of a rare killer

 © SCIEPRO/Science Photo Library/Getty

© SCIEPRO/Science Photo Library/Getty

Genetic analysis of malignant mesothelioma tumours has revealed diagnostic profiles for this rare cancer, which attacks the lung lining and usually kills within three years.

An international team, including scientists at Genentech in California, sequenced DNA and RNA from more than 200 mesothelioma tumours to build a genetic profile of the disease. Several mesothelioma tumour subtypes with different prognoses had previously been identified, but distinguishing between them during therapy remained a challenge. Four distinct gene expression patterns corresponding to different subtypes were found in the sequencing data, which will allow molecular diagnosis.

The study also revealed mutations in more than 2,000 genes in the tumours, including ten which were significantly more mutated than others. In addition, the team discovered larger alterations such as gene fusions and changes in gene splicing in the tumour samples. These profiles may help guide the care and treatment of mesothelioma patients.

Supported content

  1. Nature Genetics 83,407–416 (2017). doi: 10.1038/ng.3520

View the article on the Nature Index

1 March 2016 - 28 February 2017

International vs. domestic collaboration by WFC

  • 9.58% Domestic
  • 90.42% International

Note: Hover over the graph to view the percentage of collaboration.

Note: Collaboration is determined by the weighted fractional count (WFC), which is listed in parentheses.

Affiliated joint institutions and consortia

Return to institution outputs